For the quarter ending 2026-03-31, IKT has $173,332,227 in assets. $5,711,959 in debts.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Deferred offering costs | - | - | 385,062 | 307,373 |
| Cash and cash equivalents | 49,573,510 | 139,220,208 | 38,269,706 | 77,742,669 |
| Equipment and improvements, net | - | 0 | 0 | 23,687 |
| Marketable securities | 120,795,235 | 39,543,820 | 39,052,511 | 9,923,100 |
| Prepaid research and development | 514,910 | 1,001,993 | 210,566 | 138,855 |
| Prepaid expenses and other current assets | 1,292,813 | 343,374 | 618,783 | 682,628 |
| Total current assets | 172,176,468 | 180,109,395 | 78,536,628 | 88,794,625 |
| Right-of-use asset | - | 0 | 0 | 34,918 |
| Prepaid research and development, noncurrent | 1,000,000 | 1,000,000 | 1,000,000 | - |
| Other assets | 155,759 | 95,121 | 57,913 | - |
| Total assets | 173,332,227 | 181,204,516 | 79,594,541 | 88,853,230 |
| Lease obligation, current | - | 0 | 0 | 37,944 |
| Accounts payable | 1,587,305 | 1,158,054 | 620,528 | 2,703,554 |
| Accrued expenses and other current liabilities | 4,124,654 | 4,081,282 | 3,656,383 | 3,145,888 |
| Contingent consideration liability | 0 | 3,061,501 | 2,419,332 | 2,912,159 |
| Total current liabilities | 5,711,959 | 8,300,837 | 6,696,243 | 8,799,545 |
| Total liabilities | 5,711,959 | 8,300,837 | 6,696,243 | 8,799,545 |
| Common stock, 0.001 par value 500,000,000 and 100,000,000 shares authorized 132,032,636 and 131,691,237 shares issued and outstanding (including 0 and 4,149,252 contingently issuable shares - see note 10) at march 31, 2026 and december 31, 2025, respectively | 132,032 | 131,691 | 74,808 | 74,516 |
| Additional paid-in capital | 326,575,169 | 315,429,986 | 202,772,828 | 197,996,982 |
| Accumulated other comprehensive income (loss) | -26,293 | 21,802 | -4,189 | -2,944 |
| Accumulated deficit | -159,060,640 | -142,679,800 | -129,945,149 | -118,014,869 |
| Total stockholders' equity | 167,620,268 | 172,903,679 | 72,898,298 | 80,053,685 |
| Total liabilities and stockholders' equity | 173,332,227 | 181,204,516 | 79,594,541 | 88,853,230 |
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT)